Elecsys cobas e411

Measurement of plasma NT‐proBNP and hsTnT has been previously described.24 NT‐proBNP and hsTnT concentrations were determined by electro‐chemiluminescence immunoassay using the NT‐proBNP II and troponin T high‐sensitivity assays, respectively, on an ELECSYS Cobas e411 immunoanalyzer (Roche Diagnostics GmbH, Mannheim, Germany). The ranges of measurement for NT‐proBNP and hsTnT assays were 5 to 35 000 pg/mL and 3 to 10 000 pg/mL, respectively. Mean concentrations and interassay coefficient of variation of samples used for quality control, presented as mean (coefficient of variation), were established in‐house. Low‐concentration NT‐proBNP and hsTnT quality control samples averaged at 141 pg/mL (3.38%) and 26.7 pg/mL (6.66%), respectively; high NT‐proBNP and hsTnT samples averaged at 4759 pg/mL (4.03%) and 2090 pg/mL (4.06%), respectively.
A multiplex biomarker panel based on proximity extension technology was also utilized to get relative quantification on a panel of 92 biomarkers (Proseek Multiplex CVD I, Olink Proteomics AB, Uppsala, Sweden).

The acquired clinical datasets were collected upon admission:
Once enrolment, blood samples (serum and plasma) were collected on the basis of inclusion criteria. The samples were centrifuged and stored at −80°C for later analysis. PCT and CRP levels were detected in a serum sample. IL-6, NGAL, and CEP-1 antibody concentrations were assessed in the plasma sample. We measured CRP by particle enhanced immunoturbidimetric assay (Beckman coulter AU5800, Brea, CA). PCT levels were measured by an electrochemiluminescence immunoassay system (Roche Elecsys cobas e 411, Switzerland). Both IL-6 (Roche Elecsys cobas e 601, Switzerland) and NGAL (Beckman coulter AU2700, Brea, CA) concentrations were detected using a turbidimetric immunoassay test. Plasma concentrations of CEP-1 antibody were measured using commercial enzyme-linked immunosorbent assay kits (Euroimmun, Germany).